Status:

COMPLETED

Early Versus Delayed Surgery for Gallstone Pancreatitis

Lead Sponsor:

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Collaborating Sponsors:

University of California, Los Angeles

Conditions:

Gallstone Pancreatitis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

While there exists consensus among surgeons that patients with gallstone pancreatitis should undergo cholecystectomy to prevent recurrence, the precise timing of laparoscopic cholecystectomy for mild ...

Detailed Description

Acute pancreatitis is a common diagnosis worldwide, with more than 220,000 cases reported annually in the United States alone. The leading etiology is gallstones.1 Gallstone pancreatitis is thought to...

Eligibility Criteria

Inclusion

  • All adults are included between the age of 18 and 100 with mild to moderate gallstone pancreatitis.
  • A subject is classified as having gallstone pancreatitis if they had the following:
  • upper abdominal pain, nausea, vomiting and epigastric tenderness;
  • absence of ethanol abuse;
  • elevated amylase level to at least twice the upper limit of normal and elevated lipase level to at lease three times the upper limit of normal; and
  • imaging confirmation of gallstones.
  • The classification of mild to moderate pancreatitis is defined by the presence of the following:
  • three or fewer Ranson's criteria on admission: age \> 55 years, glucose \> 200 mg/dL , LDH\> 350 mg/dL, AST \> 250 units/L, and WBC\>16 K/mm3;
  • clinical stability with admission to a non-monitored ward bed;
  • absence of acute cholangitis: defined as a temperature \>38.6°C, right upper quadrant pain and tenderness, and significant hyperbilirubinemia; and
  • low suspicion for a retained common bile duct (CBD) stone (total bilirubin \<4 mg/dl on admission).

Exclusion

  • Severe pancreatitis (as defined by the presence of more than three Ranson's criteria on admission);
  • Suspected concomitant acute cholangitis;
  • High suspicion for retained common bile duct stone (total bilirubin ≥ 4 mg/dl on admission or ultrasound demonstration of CBD stone);
  • Patient refusal to participate;
  • Severe preexisting medical comorbidities contraindicating cholecystectomy (as determined by the primary physicians);
  • Pregnancy,
  • Prior gastric bypass surgery (making ERC difficult )
  • Admission to a monitored unit. The need for admission to a monitored bed is determined by the admitting surgeon and is guided primarily by a need for aggressive fluid administration as demonstrated by severe volume depletion (e.g., admission tachycardia \>110 beats/minute, blood urea nitrogen \> 15 mg/dl) or evidence of cholangitis.

Key Trial Info

Start Date :

November 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2009

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00863642

Start Date

November 1 2007

End Date

November 1 2009

Last Update

September 27 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Harbor-UCLA Medical Center

Torrance, California, United States, 90509